Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern

Simple item page
dc.citation.firstpage3655en_US
dc.citation.issueNumber26en_US
dc.citation.journalTitleVaccineen_US
dc.citation.lastpage3663en_US
dc.citation.volumeNumber40en_US
dc.contributor.authorPollet, Jeroenen_US
dc.contributor.authorStrych, Ulrichen_US
dc.contributor.authorChen, Wen-Hsiangen_US
dc.contributor.authorVersteeg, Leroyen_US
dc.contributor.authorKeegan, Brianen_US
dc.contributor.authorZhan, Binen_US
dc.contributor.authorWei, Junfeien_US
dc.contributor.authorLiu, Zhuyunen_US
dc.contributor.authorLee, Jungsoonen_US
dc.contributor.authorKundu, Rahkien_US
dc.contributor.authorAdhikari, Rakeshen_US
dc.contributor.authorPoveda, Cristinaen_US
dc.contributor.authorJose Villar, Mariaen_US
dc.contributor.authorRani Thimmiraju, Syamalaen_US
dc.contributor.authorLopez, Briannaen_US
dc.contributor.authorGillespie, Portia M.en_US
dc.contributor.authorRonca, Shannonen_US
dc.contributor.authorKimata, Jason T.en_US
dc.contributor.authorReers, Martinen_US
dc.contributor.authorParadkar, Vikramen_US
dc.contributor.authorHotez, Peter J.en_US
dc.contributor.authorElena Bottazzi, Mariaen_US
dc.contributor.orgJames A. Baker III Institute for Public Policyen_US
dc.date.accessioned2022-06-08T15:58:47Zen_US
dc.date.available2022-06-08T15:58:47Zen_US
dc.date.issued2022en_US
dc.description.abstractWe conducted preclinical studies in mice using a yeast-produced SARS-CoV-2 RBD subunit vaccine candidate formulated with aluminum hydroxide (alum) and CpG deoxynucleotides. This formulation is equivalent to the CorbevaxTM vaccine that recently received emergency use authorization by the Drugs Controller General ofIndia. We compared the immune response of mice vaccinated with RBD/alum to mice vaccinated with RBD/alum + CpG. We also evaluated mice immunized with RBD/alum + CpG and boosted with RBD/alum. Mice were immunized twice intramuscularly at a 21-day interval. Compared to two doses of the /alum formulation, the RBD/alum + CpG vaccine induced a stronger and more balanced Th1/Th2 cellular immune response, with high levels of neutralizing antibodies against the original Wuhan isolate of SARS-CoV-2 as well as the B.1.1.7 (Alpha), B.1.351 (Beta), B.1.617.2 and (Delta) variants. Neutralizing antibody titers against the B.1.1.529 (BA.1, Omicron) variant exceeded those in human convalescent plasma after Wuhan infection but were lower than against the other variants. Interestingly, the second dose did not benefit from the addition of CpG, possibly allowing dose-sparing of the adjuvant in the future. The data reported here reinforces that the RBD/alum + CpG vaccine formulation is suitable for inducing broadly neutralizing antibodies against SARS-CoV-2, including variants of concern.en_US
dc.identifier.citationPollet, Jeroen, Strych, Ulrich, Chen, Wen-Hsiang, et al.. "Receptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concern." <i>Vaccine,</i> 40, no. 26 (2022) Elsevier: 3655-3663. https://doi.org/10.1016/j.vaccine.2022.05.007.en_US
dc.identifier.digital1-s2-0-S0264410X22005771-mainen_US
dc.identifier.doihttps://doi.org/10.1016/j.vaccine.2022.05.007en_US
dc.identifier.urihttps://hdl.handle.net/1911/112444en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsThis is an open access article under the CC BY licenseen_US
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/en_US
dc.titleReceptor-binding domain recombinant protein on alum-CpG induces broad protection against SARS-CoV-2 variants of concernen_US
dc.typeJournal articleen_US
dc.type.dcmiTexten_US
dc.type.publicationpublisher versionen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
1-s2-0-S0264410X22005771-main.pdf
Size:
1.35 MB
Format:
Adobe Portable Document Format
Download
Collections
Faculty Publications
Rice Coronavirus Research